Twin Tree Management
TGTX icon

Twin Tree Management’s TG Therapeutics TGTX Stock Holding History

Twin Tree Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.8K Buy
+1,800
New +$53.6K ﹤0.01% 1187
2025
Q3 		– Sell
-78,600
Closed -$2.83M – 1833
2025
Q2 		$2.83M Buy
+78,600
New +$2.93M 0.01% 1169
2023
Q4 		– Sell
-16,400
Closed -$137K – 1587
2023
Q3 		$137K Hold
16,400
– – ﹤0.01% 1096
2023
Q2 		$407K Buy
+16,400
New +$424K ﹤0.01% 1074

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Twin Tree Management's TGTX Position: Q3 2025 in Review

Twin Tree Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 27,655 shares — an estimated $995K sold.

Twin Tree Management first reported a position in TGTX in Q2 2023 and held it in 5 quarters. The position peaked at $995K in Q2 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Twin Tree Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Twin Tree Management sold 27,655 TG Therapeutics shares in Q3 2025, an estimated $995K.
  • Twin Tree Management first reported a position in TG Therapeutics in Q2 2023 and held it in 5 quarters.
  • Twin Tree Management's TG Therapeutics position peaked at $995K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Twin Tree Management's 13F filing for Q3 2025, filed 13 Nov 2025.